Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infants who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the PMS.~* A male or female infant from the age of 6 weeks at the time of the first vaccination.~* Written informed consent obtained from the parent or guardian of the infant.~Exclusion Criteria:~• At the time of PMS entry, the contraindications and precautions of use indicated in the prescribing information should be checked and the infant must not be included in the PMS if there is any contraindication. Any changes in the locally approved Prescribing Information must be implemented immediately.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 24 Weeks
- Healthy Volunteers: t

Study Arms:
- Rotarix Group (Type: None): Subjects who received 2 oral doses of Rotarix. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).